Back to results
US 10,092,677 B2Granted
Natural tissue scaffolds as tissue fillers
AssigneeLifeCell Corporation
InventorsHui Xu, Wenquan Sun, Hua Wan, Rick T. Owens
Life of this patent
Estimating the term…
Abstract
Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.
Claims23
A tissue treatment composition, comprising:
- an adipose acellular tissue matrix having a stable three-dimensional structure, having the ability to maintain the same shape, size, and sponge property after being implanted for one week as was observed prior to implantation;
- and
- at least one of exogenous hyaluronic acid (HA) and exogenous decorin on a surface of the adipose acellular tissue matrix at a concentration that reduces an inflammatory response or fibrosis when the composition is implanted in a body as compared to the same composition not comprising hyaluronic acid or decorin.
A tissue treatment composition, comprising:
- an adipose acellular tissue matrix having a stable three-dimensional structure, having the ability to maintain the same shape, size, and sponge property after being implanted for one week as was observed prior to implantation;
- and
- at least one of exogenous hyaluronic acid (HA) and exogenous decorin contained in the adipose acellular tissue matrix at a concentration that reduces an inflammatory response or fibrosis when the composition is implanted in a body as compared to the same composition not comprising hyaluronic acid or decorin.
A tissue treatment composition, comprising:
- an adipose tissue matrix from which substantially all viable cells have been removed having a stable three-dimensional structure, having the ability to maintain the same shape, size, and sponge property after being implanted for one week as was observed prior to implantation;
- and
- at least one of exogenous hyaluronic acid (HA) and exogenous decorin on a surface of the adipose tissue matrix at a concentration that reduces an inflammatory response or fibrosis when the composition is implanted in a tissue defect as compared to the same composition not comprising hyaluronic acid or decorin.
Dependencies are inferred from the claim text.